FDA Approves First Pan-RAS Inhibitor Daraxonrasib for Metastatic Pancreatic Adenocarcinoma

The FDA recently approved daraxonrasib as the first pan-RAS inhibitor for metastatic pancreatic adenocarcinoma, a decision that has sparked debate regarding the evidence supporting its clinical usage.

  • In clinical trials, tumors stopped growing in nearly all of the 61 participants.
  • One in 12 patients saw their cancer become undetectable on CT scans during the trial.
  • Survival rates one year after treatment reached 76.6%, compared to 40–45% with standard chemotherapy.

The approval covers two specific groups: patients who have undergone at least one prior systemic therapy and those unable to tolerate multiagent regimens. Vivek Subbiah, Director of the Early Phase Drug Development Program at NYU Langone Health, said that while trials typically enroll patients with high performance status, the reality of clinical practice is often different.

“Most of our patients never get to second-line therapy because their condition declines first. So the imprecision in the label is what gives those patients access,” Subbiah told Oncodaily – Oncology News, Insights, Stories.

The drug, which functions by locking onto and disabling specific mutations that drive tumor growth, has been described as a major advance for a condition with historically low survival rates. During this period, 90% of patients saw their tumors stop growing, while over 60% experienced tumor shrinkage or disappearance.

“We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival,” Dr. Wungki Park of Memorial Sloan Kettering Cancer Center said, as reported by The Guardian and BBC.

“Just imagine, in an average of 18 months your disease just disappears on the CT scan … that’s closest to complete remission … it’s incredible.”

Future applications for KRAS mutations

Because daraxonrasib functions by locking onto and disabling specific mutations that drive tumor growth, researchers believe the treatment may eventually benefit patients with other types of cancer. Dozens of additional conditions, such as ovarian and lung cancer, often carry similar mutations that the drug is designed to target.

Dr. Sam Godfrey of Cancer Research UK told BBC News that he hopes the early success observed in pancreatic cancer can be effectively rolled out to these other malignancies. Experts remain optimistic that the drug’s mechanism of action could address a broad range of cancers that have historically proven difficult to treat.

Ongoing requirements for clinical validation

While the drug has already received approval in the US, health officials emphasize that more trials are required before it can be assessed for use on the NHS. Despite the positive trial results, doctors caution that pancreatic cancer remains notoriously hard to treat and continues to have the lowest survival rate of all common cancers in the UK.

Photo: The Guardian

Dr. Sam Godfrey said that the results were incredibly exciting, stating, “We are finally seeing progress in pancreatic cancer which is so long overdue.” However, researchers warn that longer studies are necessary to determine if the treatment can consistently put cancers into remission and how long those effects might last.

Hope for Advanced Treatment

Cancer Research UK called it “the biggest leap forward in decades” for pancreatic cancer patients. “We are finally seeing progress in pancreatic cancer which is so long overdue,” Dr. Sam Godfrey of Cancer Research UK told the BBC.

Vivek Subbiah, the Director of the Early Phase Drug Development Program at NYU Langone Health’s Perlmutter Cancer Center, brings over 15 years of experience in oncology drug development and precision medicine to his assessment of the drug’s labeling. Having led more than 200 clinical trials and contributed to the development of 12 FDA-approved drugs, Subbiah specializes in biomarker-driven clinical research and tumor-agnostic therapies.

His extensive background—which includes serving as the Center Medical Director of the Early-Phase Clinical Trials Program at MD Anderson Cancer Center—informs his view that broad regulatory labels are essential for expanding patient access, particularly when clinical realities often prevent patients from reaching later lines of therapy.

Despite the optimism, experts caution that the pill is not currently classified as a cure. Researchers intend to use real-world evidence to address remaining uncertainties regarding the drug’s long-term efficacy. “Until then, I think this is a case where an imprecise label serves precision medicine well,” Subbiah told Oncodaily – Oncology News, Insights, Stories.

Photo of author

Health Desk

Health Desk at Archyde.

NYC Administration Releases 84,000 More 9/11 Records; Portal Tops 11M Visits

Valtra Has Launched the Sixth Generation of Its T Series Tractors